Abstract “Financial toxicity” has now become a familiar term used in the discussion of cancer
drugs, and it is gaining traction in the literature given the high price of newer classes of …

Globally, annual spending on anticancer drugs is around US $100 billion, and is predicted
to rise to $150 billion by 2020. In the USA, a novel anticancer drug routinely costs more than …

Purpose Patients with cancer are more likely to file for bankruptcy than the general
population, but the impact of severe financial distress on health outcomes among patients …

Financial toxicity describes the financial burden and distress that can arise for patients, and
their family members, as a result of cancer treatment. It includes direct out-of-pocket costs for …

Objective To determine the extent of financial toxicity (FT) among cancer survivors, identify
the determinants and how FT is measured. Methods A systematic review was performed in …

BACKGROUND Cancer‐related financial burden has been linked to cancer survivors (CS)
forgoing/delaying medical care, skipping follow‐up visits, and discontinuing medications. To …

Background: Out-of-pocket costs pose a substantial economic burden to cancer patients and
their families. The purpose of this study was to evaluate the literature on out-of-pocket costs …

The rising medical costs associated with cancer have led to considerable financial hardship
for patients and their families in the United States. Using data from the LIVESTRONG 2012 …

Molecular and immune therapies have revolutionized cancer treatment and improved
patient outcomes and survival. However, the pricing of these drugs has become an issue as …

Importance Medicare beneficiaries with cancer are at risk for financial hardship given
increasingly expensive cancer care and significant cost sharing by beneficiaries. Objectives …